Merck & Co., Inc. reported strong Q3 2025 profitability concurrent with significant strategic investment and material operational headwinds in specific product lines.
Financial Performance (Q3 2025 YoY): Total Sales grew 4% to $17.3B, driven by a 15% jump in U.S. sales, though international sales fell 8%. Net Income surged to $5.79B (vs. $3.16B in 3Q 2024), pushing Diluted EPS to $2.32 (vs. $1.24). Gross Margin improved to 77.7%. For the nine months ended Sept 30, Net Income reached $15.30B, with Diluted EPS at $6.08. R&D expenses dropped 28% for the quarter compared to Q3 2024.
*
...